iPROLEPSIS | iPROLEPSIS: PSORIATIC ARTHRITIS INFLAMMATION EXPLAINED THROUGH MULTI-SOURCE DATA ANALYSIS GUIDING A NOVEL PERSONALISED DIGITAL CARE ECOSYSTEM

Summary
Psoriatic Arthritis (PsA) is a chronic, progressive, inflammatory disease affecting 1-2% of the general population, while manifesting in up to 30% of people with psoriasis (PsO). The transition from health to PsA is currently untraceable; diagnosis of early PsA is challenging even in PsO patients. Untimely diagnosis is common and contributes to early deterioration of quality of life, also increasing the burden of the multiple comorbidities associated with PsA. In this vein, iPROLEPSIS aspires to shed light upon the health-to-PsA transition with a comprehensive multiscale/multifactorial PsA model employing novel trustworthy AI-based analysis of multisource and heterogenous (i.a., in-depth health, environmental, genetic, behavioural) data, digital phenotyping of inflammatory symptoms with emphasis on tracking of motor manifestations using smart devices and wearables, novel optoacoustic imaging-based markers of PsA in the skin and joints, and investigation of the role of mast cells in the PsA transition, to identify key drivers of the disease and support personalized models for PsA risk/progression prediction and monitoring as well as associated inflammation detection and severity assessment. To ultimately advance PsA diagnosis and care, the models will be translated into a digital health ecosystem comprising dependable tools for supporting healthcare professionals in disease screening, monitoring and treatment via quantitative, explainable evidence, and empowering people with/at risk of PsA with tailored insights and preventive interventions based on actionable factors for educated health management. The project will steer its research and development efforts following a trustworthy framework for ethical, lawful, and robust AI, and a user-centered co-creation approach based on constant involvement of key stakeholders during the design, development, and testing of the digital health ecosystem, securing successful integration of the latter in the continuum of care.
Unfold all
/
Fold all
More information & hyperlinks
Web resources: https://cordis.europa.eu/project/id/101095697
Start date: 01-01-2023
End date: 31-12-2026
Total budget - Public funding: 6 485 500,00 Euro - 6 485 500,00 Euro
Cordis data

Original description

Psoriatic Arthritis (PsA) is a chronic, progressive, inflammatory disease affecting 1-2% of the general population, while manifesting in up to 30% of people with psoriasis (PsO). The transition from health to PsA is currently untraceable; diagnosis of early PsA is challenging even in PsO patients. Untimely diagnosis is common and contributes to early deterioration of quality of life, also increasing the burden of the multiple comorbidities associated with PsA. In this vein, iPROLEPSIS aspires to shed light upon the health-to-PsA transition with a comprehensive multiscale/multifactorial PsA model employing novel trustworthy AI-based analysis of multisource and heterogenous (i.a., in-depth health, environmental, genetic, behavioural) data, digital phenotyping of inflammatory symptoms with emphasis on tracking of motor manifestations using smart devices and wearables, novel optoacoustic imaging-based markers of PsA in the skin and joints, and investigation of the role of mast cells in the PsA transition, to identify key drivers of the disease and support personalized models for PsA risk/progression prediction and monitoring as well as associated inflammation detection and severity assessment. To ultimately advance PsA diagnosis and care, the models will be translated into a digital health ecosystem comprising dependable tools for supporting healthcare professionals in disease screening, monitoring and treatment via quantitative, explainable evidence, and empowering people with/at risk of PsA with tailored insights and preventive interventions based on actionable factors for educated health management. The project will steer its research and development efforts following a trustworthy framework for ethical, lawful, and robust AI, and a user-centered co-creation approach based on constant involvement of key stakeholders during the design, development, and testing of the digital health ecosystem, securing successful integration of the latter in the continuum of care.

Status

SIGNED

Call topic

HORIZON-HLTH-2022-STAYHLTH-02-01

Update Date

09-02-2023
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
Horizon Europe
HORIZON.2 Global Challenges and European Industrial Competitiveness
HORIZON.2.1 Health
HORIZON.2.1.1 Health throughout the Life Course
HORIZON-HLTH-2022-STAYHLTH-02
HORIZON-HLTH-2022-STAYHLTH-02-01 Personalised blueprint of chronic inflammation in health-to-disease transition